Current Report Filing (8-k)
May 13 2019 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 13, 2019
Avenue Therapeutics, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
|
001-38114
(Commission File Number)
|
|
47-4113275
(IRS Employer Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act.
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock
|
|
ATXI
|
|
Nasdaq Capital
Market
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On May 13, 2019, Avenue
Therapeutics, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter
ended March 31, 2019. A copy of such press release is being furnished as Exhibit 99.1 to this report.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Avenue Therapeutics, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
Date: May 13, 2019
|
|
|
|
|
|
|
|
|
By:
|
/s/ Lucy Lu, M.D.
|
|
|
|
Lucy Lu, M.D.
|
|
|
|
President and Chief Executive Officer
|
|
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Apr 2023 to Apr 2024